Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule dire… Read more
Market Cap & Net Worth: Ovid Therapeutics Inc (OVID)
Ovid Therapeutics Inc (NASDAQ:OVID) has a market capitalization of $163.79 Million ($163.79 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18195 globally and #6796 in its home market, demonstrating a 7.98% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ovid Therapeutics Inc's stock price $2.30 by its total outstanding shares 71212353 (71.21 Million).
Ovid Therapeutics Inc Market Cap History: 2017 to 2026
Ovid Therapeutics Inc's market capitalization history from 2017 to 2026. Data shows change from $702.87 Million to $163.79 Million (-17.18% CAGR).
Index Memberships
Ovid Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.20 Trillion | 0.00% | #497 of 976 |
|
NASDAQ Composite
IXIC
|
$32.97 Trillion | 0.00% | #1682 of 3165 |
Weight: Ovid Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ovid Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ovid Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
117.48x
Ovid Therapeutics Inc's market cap is 117.48 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $164.50 Million | $12.62 Million | -$80.73 Million | 13.04x | N/A |
| 2021 | $228.59 Million | $208.38 Million | $122.83 Million | 1.10x | 1.86x |
| 2022 | $132.45 Million | $1.50 Million | -$51.41 Million | 88.14x | N/A |
| 2023 | $229.30 Million | $392.00K | -$52.34 Million | 584.96x | N/A |
| 2024 | $66.49 Million | $566.00K | -$26.43 Million | 117.48x | N/A |
Competitor Companies of OVID by Market Capitalization
Companies near Ovid Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Ovid Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Ovid Therapeutics Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, Ovid Therapeutics Inc's market cap moved from $702.87 Million to $ 163.79 Million, with a yearly change of -17.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $163.79 Million | +41.10% |
| 2025 | $116.08 Million | +74.57% |
| 2024 | $66.49 Million | -71.00% |
| 2023 | $229.30 Million | +73.12% |
| 2022 | $132.45 Million | -42.06% |
| 2021 | $228.59 Million | +38.96% |
| 2020 | $164.50 Million | -44.34% |
| 2019 | $295.53 Million | +71.49% |
| 2018 | $172.33 Million | -75.48% |
| 2017 | $702.87 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Ovid Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $163.79 Million USD |
| MoneyControl | $163.79 Million USD |
| MarketWatch | $163.79 Million USD |
| marketcap.company | $163.79 Million USD |
| Reuters | $163.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.